導(dǎo)師簡(jiǎn)介

姓名：閆喆一  性別：女  政治面貌：中共黨員

學(xué)歷：博士研究生  學(xué)位：博士  職稱：副主任醫(yī)師

博、碩導(dǎo)師：碩士生導(dǎo)師  本崗位工作年數(shù)：12年

研究方向：糖尿病視網(wǎng)膜病變的機(jī)制與早期干預(yù)研究

榮譽(yù)稱號(hào)：無

學(xué)術(shù)任職：山西省健康協(xié)會(huì)眼預(yù)防保健專委會(huì)委員；山西醫(yī)科大學(xué)細(xì)胞生理學(xué)教育部重點(diǎn)實(shí)驗(yàn)室成員

近五年承擔(dān)科研課題情況：

(1)國家自然基金青年項(xiàng)目，CTRP3血癥的失保護(hù)作用及其機(jī)理研究, 2020-01-01 至 2022-12-31, 21萬元, 已結(jié)題, 主持

(2) 中國博士后科學(xué)基金會(huì), 中國博士后科學(xué)基金面上資助, 2018YFA0107400, 低CTRP3血癥在糖尿病視網(wǎng)膜病變（DR）早期血管舒張障礙中的作用及機(jī)制研究, 2019-12 至 2022-01, 8萬元, 結(jié)題, 主持  

(3) 山西省人社廳, 留學(xué)人員科技活動(dòng)擇優(yōu)資助項(xiàng)目, 20210021, 脂肪因子CTRP3對(duì)糖尿病視網(wǎng)膜病變（DR)的抑制作用及機(jī)制研究, 2021-06 至 2023-06, 8萬元, 在研, 主持

(4)山西省科技廳基礎(chǔ)研究計(jì)劃面上項(xiàng)目，小分子靶向VEGF抑制劑WithaferinA在糖尿病視網(wǎng)膜病変中的作用及其機(jī)制研究2023-6-1至2023-5-31, 10萬元, 在研, 主持

代表性論著及近五年的代表性論文（限10項(xiàng)以內(nèi)）：

(1) Yan Z, Wang C, Meng Z, et al. C1q/TNF-Related Protein 3 Prevents Diabetic Retinopathy via AMPK-Dependent Stabilization of Blood–Retinal Barrier Tight Junctions[J]. Cells, 2022, 11(5): 779.（IF:7.66）

(2)Yan Z, Cao X, Wang C, et al. C1q/tumor necrosis factor-related protein-3 improves microvascular endothelial function in diabetes through the AMPK/eNOS/NO· signaling pathway[J]. Biochemical Pharmacology, 2022, 195: 114745.（Top, IF:6.1）

(3)Yan Z, Zhang Y, Wang C, et al. Withaferin a Attenuates Retinal Ischemia-Reperfusion Injury via Akt-Dependent Inhibition of Oxidative Stress[J]. Cells, 2022, 11(19): 3113（IF:7.66）

(4)Yan Z, Guo R, Gan L, et al. Withaferin A inhibits apoptosis via activated Akt-mediated inhibition of oxidative stress[J]. Life sciences, 2018, 211: 91-101.（IF:6.78）

(5)Yan Z, Zhao J, Gan L, et al. CTRP3 is a novel biomarker for diabetic retinopathy and inhibits HGHL-induced VCAM-1 expression in an AMPK-dependent manner[J]. PloS one, 2017, 12(6): e0178253.（IF:3.75）

(6)Yan, W., Guo, Y., Tao, L., Lau, W. B., Gan, L., Yan, Z., ... & Ma, X. L. (2017). C1q/tumor

necrosis factor–related protein-9 regulates the fate of implanted mesenchymal stem cells and

mobilizes their protective effects against ischemic heart injury via multiple novel signaling pathways. Circulation, 136(22), 2162-2177.（IF:39.92）

(7)Wang, Y., Liang, B., Lau, W. B., Du, Y., Guo, R., Yan, Z., ... & Ma, X. L. (2017). Restoring

diabetes-induced autophagic flux arrest in ischemic/reperfused heart by ADIPOR (adiponectin

receptor) activation involves both AMPK-dependent and AMPK-independent signaling. Autophagy, 13(11), 1855-1869.（IF:13.39）

(8)Zhang Y., Liu, C., Liu, J., Guo, R., Yan, Z., Liu, W et al. Implications of C1q/TNF-related

protein superfamily in patients with coronary artery disease[J]. Scientific Reports, 2020, 10(1): 1-11. （IF:4.99）

(9)Guo, R., Gan, L., Lau, W. B., Yan, Z., Xie, D., Gao, E., ... & Wang, Y. (2019). Withaferin A

prevents myocardial ischemia/reperfusion injury by upregulating AMP-activated protein

kinase-dependent B-cell lymphoma2 signaling. Circulation Journal, 83(8), 1726-1736.（ IF:3.35）